Teva Pharmaceutical Industries has entered into a $120 million pharma licensing agreement that will allow it to distribute and promote a competitor to its own cancer drug, Eagle Pharmaceuticals EP-3102.
Eagle’s non-Hodgkin’s lymphoma drug EP-3102 competes directly with Teva’s Treanda, because both drugs target chronic lymphocytic leukemia.
The two companies said they will now settle a patent infringement lawsuit that had been brewing between them in U.S. District Court for the District of Delaware.
|Searching for more deal information? Current Partnering offers the following options:
Under the terms of the pharma licensing deal, Teva will shell out $30 million in cash, which will be followed by $90 million in additional milestone payments and double- digit royalties on sales.
Teva will handle all regulatory approvals and both the costs and logistics associated with running clinical trials.
Teva also said Tuesday it will now waive its orphan-drug exclusivities for two diseases that EP-3102 also targets, a move which will put it in front of consumers much more quickly.
Eagle already has submitted a new drug application for EP-3102, a rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, to the U.S. Food and Drug Administration.
Because of its efficacy in clinical trials, it had requested priority review, a nice boost for a product which has already received orphan-drug designation the seven years of patent exclusivity that go with that demarcation.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies